Timing of Colorectal Cancer Screening: How Current Guidelines Vary

Slideshow

This slideshow reviews the latest guidelines and updates on colorectal cancer screening.

The American Cancer Society (ACS) estimates that, in 2019 alone, there will be more than 100,000 new diagnoses of colon cancer and more than 44,000 new cases of rectal cancer in the United States. Clinicians require up-to-date information on colorectal cancer screening guidelines to provide care to their patient populations. This slideshow summarizes the last recommendations from various professional organizations as well as the available screening strategies. 

Recent Videos
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
Related Content
The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

FDA Discourages Accelerated Approval of Botensilimab/Balstilimab Combo in R/R MSS CRC

Roman Fabbricatore
July 19th 2024
Article

The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

Jagoda Misniakiewicz, PharmD
June 10th 2024
Podcast

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Expert Commentary on the Product Profile of Fruquintinib in Metastatic CRC

Expert Commentary on the Product Profile of Fruquintinib in Metastatic CRC

Jagoda Misniakiewicz, PharmD
July 11th 2024
Article

Jagoda Misniakiewicz, PharmD, discussed implementing fruquintinib into clinical practice and how it's mechanism of action compares with others in the space.

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited Institutions

Steven Wexner, MD, PhD;Arielle Kanters, MD
May 27th 2024
Podcast

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Phase 1 data may warrant further investigation of lunresertib in high-risk gastrointestinal tumors with CCNE1 amplifications or FBXW7 mutations.

Lunresertib Combo Shows Responses in Advanced Pretreated GI Cancer Subtypes

Chris Ryan
June 29th 2024
Article

Phase 1 data may warrant further investigation of lunresertib in high-risk gastrointestinal tumors with CCNE1 amplifications or FBXW7 mutations.

HRQOL data from the CheckMate 8HW trial may further support frontline nivolumab/ipilimumab for those with MSI-H or dMMR metastatic colorectal cancer.

Nivolumab Combo Improves HRQOL Vs Chemo in MSI-H/dMMR Metastatic CRC

Russ Conroy
June 28th 2024
Article

HRQOL data from the CheckMate 8HW trial may further support frontline nivolumab/ipilimumab for those with MSI-H or dMMR metastatic colorectal cancer.